Levetiracetam Versus Oxcarbazepine as Monotherapy to Evaluate Efficacy and Safety in Subjects With Newly or Recently Diagnosed Partial Epilepsy

PHASE4CompletedINTERVENTIONAL
Enrollment

353

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Epilepsy
Interventions
DRUG

Levetiracetam

250 mg and 500 mg Levetiracetam tablet, 1000 mg-3000 mg/day, maximum 50 weeks including initial up titration of 500 mg/day for 2 weeks

DRUG

Oxcarbazepine

150 mg and 300 mg Oxcarbazepine tablet, 900 mg-2400 mg/day, maximum 50 weeks including 2 weeks of up titration (300 mg/day 1week then 600 mg/day 1 week)

Trial Locations (23)

Unknown

05, Busan

10, Busan

16, Busan

06, Daejeon

18, Daejeon

23, Gangwon-Do

08, Goyang-si

09, Goyang-si

07, Gwangju

22, Junggu

14, Seongnam-si

01, Seoul

02, Seoul

03, Seoul

04, Seoul

11, Seoul

12, Seoul

13, Seoul

15, Seoul

17, Seoul

20, Seoul

21, Seoul

19, Ulsan

All Listed Sponsors
lead

Korea UCB Co., Ltd.

INDUSTRY